实时连续血糖监测对妊娠期糖尿病母婴结局的影响:GRACE随机对照试验
GRACE试验为开放标签、多中心、跨国随机对照研究,纳入375例妊娠期糖尿病孕妇,比较实时连续血糖监测(rt-CGM)与自我血糖监测(SMBG)对大于胎龄儿(LGA)比例的影响。
要点
- rt-CGM可降低妊娠期糖尿病孕妇LGA新生儿发生率。
- 严重不良事件在两组间无显著差异。
- 小于胎龄儿(SGA)总体发生率高于预期,需进一步研究。
核心结论
- 在妊娠期糖尿病孕妇中,使用rt-CGM可减少LGA出生,且不增加严重不良事件。
- SGA婴儿总体发生率高于预期,可能与队列中严格血糖控制有关,需进一步研究。
研究设计与样本
- 开放标签、平行组、多中心、跨国随机对照试验,在奥地利、德国和瑞士的四所大学医院进行。
- 纳入年龄18-55岁、单胎妊娠、根据IADPSG标准诊断妊娠期糖尿病的孕妇,随机分配至rt-CGM组(n=190)或SMBG组(n=185)。
- 主要终点为LGA新生儿比例,按意向性治疗人群分析;SMBG组在随机后和36-38周使用盲法CGM 10天,rt-CGM组使用开放rt-CGM至分娩。
关键数值与推荐
- 妊娠期糖尿病诊断依据国际糖尿病与妊娠研究组协会(IADPSG)标准。
- LGA定义采用围产研究所GROW定制出生体重百分位。
临床怎么用
- 对于妊娠期糖尿病孕妇,可考虑使用rt-CGM以降低LGA新生儿风险。
- 使用rt-CGM时需关注SGA风险,本研究中SGA发生率高于预期。
局限性
- 开放标签设计可能引入偏倚。
- 主要终点分析仅纳入有数据者(rt-CGM组170例,SMBG组175例),非全部随机人群。
- SGA发生率高于预期,需进一步研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data regarding the impact of real-time continuous glucose monitoring (rt-CGM) on reducing adverse pregnancy outcomes in women with gestational diabetes are contradictory. We aimed to assess differences in the proportion of large-for-gestational-age (LGA) newborns between women using rt-CGM versus self-monitoring of blood glucose (SMBG). METHODS: For this open-label, parallel-group, multicentre, randomised controlled trial, women aged 18-55 years with singleton pregnancy and gestational diabetes (diagnosed according to the International Association of the Diabetes and Pregnancy Study Groups criteria), were randomly assigned (1:1) to rt-CGM or SMBG. The first allocation was by chance; for subsequent allocations, minimisation was used to balance three prespecified factors: gestational age at study entry, previous gestational diabetes, and preconceptional BMI. SMBG participants used blinded CGM for 10 days after randomisation and at 36-38 weeks; rt-CGM participants used open rt-CGM until delivery. All were managed according to standard care protocols in four university hospitals in Austria, Germany, and Switzerland. The primary endpoint was the proportion of LGA newborns (using the Perinatal Institute's GROW customised birthweight percentiles), assessed in the intention-to-treat population. Secondary endpoints included the requirement for glucose-lowering medication, CGM metrics, and non-glycaemic maternal and neonatal outcomes. Recruitment and follow-up are complete. This study is registered with ClinicalTrials.gov (NCT03981328). FINDINGS: Between Aug 24, 2020, and May 30, 2024, 610 women were screened for eligibility, of whom 375 (diagnosed with gestational diabetes at a mean of 25·2 weeks [SD 2·3] of gestation), were randomly assigned to rt-CGM (n=190) or SMBG (n=185) at a mean of 28·6 weeks (SD 1·9) of gestation. 170 intervention and 175 control participants with available data were assessed for the primary endpoint. LGA neonates were born to six (4%) of 170 rt-CGM and 18 (10%) of 175 SMBG participants (OR 0·32, 95% CI 0·10-0·87, p=0·014). Small-for-gestational-age (SGA) neonates were born to 33 (19%) and 23 (13%) participants, respectively (OR 1·59, 0·86-2·99, p=0·11). Serious adverse events occurred in 23 (12%) of 190 versus 28 (15%) of 185 participants (OR 0·77, 0·42-1·40, p=0·39). INTERPRETATION: rt-CGM use in women with gestational diabetes reduced LGA births, without differences in serious adverse events. The higher-than-expected overall prevalence of SGA infants, possibly related to the tight glycaemic control in our cohort, requires further research. FUNDING: Dexcom. TRANSLATION: For the German translation of the abstract see Supplementary Materials section.
引用
- Linder T, Dressler-Steinbach I, Wegener S, et al. Glycaemic control and pregnancy outcomes with real-time continuous glucose monitoring in gestational diabetes (GRACE): an open-label, multicentre, multinational, randomised controlled trial. Lancet Diabetes Endocrinol. 2025. PMID: 41308662. doi:10.1016/S2213-8587(25)00288-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。